MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
37.27
+0.02
+0.05%
After Hours: 37.27 0 0.00% 19:30 11/13 EST
OPEN
36.80
PREV CLOSE
37.25
HIGH
38.70
LOW
36.28
VOLUME
695.17K
TURNOVER
--
52 WEEK HIGH
109.00
52 WEEK LOW
33.40
MARKET CAP
1.27B
P/E (TTM)
-5.7812
1D
5D
1M
3M
1Y
5Y
1D
How Investors Are Reacting To Nektar Therapeutics (NKTR) Phase 3 Trial Starts
Simply Wall St · 22h ago
Nektar Therapeutics Earnings Call Signals Clinical Momentum
TipRanks · 1d ago
Nektar Therapeutics (NKTR) Has Investors Asking A Bigger Question
Simply Wall St · 1d ago
Nektar (NKTR) Q3 2026 Earnings Call Transcript
The Motley Fool · 2d ago
Nektar price target lowered to $40 from $50 at Wedbush
TipRanks · 2d ago
Piper Sandler Keeps Their Buy Rating on Nektar Therapeutics (NKTR)
TipRanks · 2d ago
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
TipRanks · 2d ago
Nektar Therapeutics Q3 EPS $(1.63) Beats $(2.08) Estimate, Sales $9.386M Miss $10.274M Estimate. Cash and Investments $952.9M
Benzinga · 3d ago
More
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.